Clinical Trial Update: BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for BPI-7711 capsule in EGFR T790M-positive non-small cell lung cancer (Phase 1/Phase 2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BPI-7711

Snippet

Sponsor: Beta Pharma Shanghai | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED